Last reviewed · How we verify
NCT06074692: PRIMA
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Phase 2 trial testing Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) in Sarcoma in 86 participants. Currently enrolling.
30 August 2026
Quick facts
| Lead sponsor | Ruijin Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 86 |
| Start date | 1 June 2023 |
| Primary completion | 30 August 2026 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
Conditions studied
- Sarcoma — all drugs for Sarcoma →
- Sarcoma,Soft Tissue — all drugs for Sarcoma,Soft Tissue →
- Sarcoma of Bone — all drugs for Sarcoma of Bone →
Sponsor
Ruijin Hospital
Who can join
Adults 10 to 70, any sex, with Sarcoma or Sarcoma,Soft Tissue. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
New strategies in soft tissue sarcoma treatment.
Spalato-Ceruso M, Ghazzi NE, Italiano A. · · 2024 · cited 26× · PMID 39218932 · DOI 10.1186/s13045-024-01580-3 -
Clinical application of immunogenic cell death inducers in cancer immunotherapy: turning cold tumors hot.
Han Y, Tian X, Zhai J, Zhang Z. · · 2024 · cited 20× · PMID 38774648 · DOI 10.3389/fcell.2024.1363121 -
Genome instability and crosstalk with the immune response.
Chabanon RM, Danlos FX, Ouali K, Postel-Vinay S. · · 2025 · cited 4× · PMID 41188872 · DOI 10.1186/s13073-025-01509-6 -
A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma.
Harris JP, Park J, Ku E, Seyedin S, et al · · 2024 · cited 2× · PMID 38449377 · DOI 10.1177/10732748241237331 -
Tumor irradiation induced immunogenic response: the impact of DNA damage induction and misrepair.
Liu Q, Shi X, Tayier N, Ma L. · · 2025 · cited 1× · PMID 40841665 · DOI 10.1186/s13014-025-02711-x -
Immunotherapy for Leiomyosarcoma: Current Status and Perspectives.
Qi H, Zhang H, Wang Q, Wang X, et al · · 2026 · PMID 42105786 · DOI 10.1155/jimr/6614578 -
Bibliometric analysis of research trends on the combination of radiotherapy and PARP inhibitors in solid tumors.
Chen Y, Zhang Z, Yin R, Li Q, et al · · 2025 · PMID 40421223 · DOI 10.3389/fphar.2025.1603573 -
Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?
Papageorgiou GI, Skouteris N, Eleftheriou K, Kosmas C. · · 2024 · PMID 39268937 · DOI 10.1080/1750743x.2024.2398412
Verify or expand the search:
- PubMed search for NCT06074692
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sarcoma
Currently open trials in the same condition.
- NCT07402577 — Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot · recruiting
- NCT07501026 — Preoperative Spatially Fractionated Radiation Therapy (SFRT) in Soft Tissue Sarcoma (neoSFRT-SARC) · Phase 2 · recruiting
- NCT07359911 — Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patient · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
Other Ruijin Hospital trials
Trials by the same sponsor.
- NCT07589361 — Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors · not yet recruiting
- NCT07449507 — Partially Hydrolyzed Whey Protein Formula for Infants With Mild Allergy · NA · not yet recruiting
- NCT07496385 — Clinical Study on the Efficacy of Subglottic Suction in Mechanically Ventilated Patients Guided by Bedside Ultrasound · NA · not yet recruiting
- NCT07511114 — A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyp · Phase 3 · not yet recruiting
- NCT07514169 — The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06074692 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ruijin Hospital
- Last refreshed: 31 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06074692.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing